At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
ADX-629 +1 moredrug
Likely dose
ADX-629 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
In Brief
A Phase 2 clinical trial evaluating ADX-629 and Placebo for Atopic Asthma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Asthma
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedJan 2021
Primary CompletionJan 2022
TodayJul 2026
First PostedJan 28, 2021
Enrollment StartJan 9, 2021
Primary CompletionJan 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.4 years ago
Interventions
ADX-629drug
ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
Placebodrug
Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week